Director Joseph P. Slattery filed a Form 144 notice with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing a proposed sale of 5,200 shares of Replimune Group, Inc. common stock through Morgan Stanley Smith Barney LLC.

Key Highlights

  • Seller: Joseph P. Slattery, identified in the filing as a Director of Replimune Group, Inc.
  • Shares proposed for sale: 5,200 shares of common stock, with an aggregate market value of $113,360.00 as reported in the filing.
  • Approximate sale date: November 9, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Original acquisition: The 5,200 shares were acquired on July 20, 2018, via exercised shares from the issuer, with payment made in cash on July 20, 2018.
  • Shares outstanding: The filing reports 94,800,404 shares of common stock outstanding at the time of notice.
  • Prior three-month sales: The filing states "Nothing to Report" for securities sold during the past three months by the person filing the notice.

Replimune Director Files Rule 144 Notice for Proposed Common Stock Sale

According to the Form 144 filing, Joseph P. Slattery, a Director of Replimune Group, Inc. (NASDAQ:REPL), has provided notice of a proposed sale of 5,200 shares of the company's common stock. The filing lists the aggregate market value of the shares at $113,360.00. The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, with an approximate sale date of November 9, 2026.

The filing discloses that the shares proposed for sale were originally acquired on July 20, 2018, through an exercise of shares from the issuer, with full payment made in cash on the same date. The filing notes that Replimune Group, Inc. had 94,800,404 shares of common stock outstanding at the time the notice was submitted. The company's registered address is listed as 500 Unicorn Park Drive, Suite 303, Woburn, Massachusetts 01801.

The filer represented, by signing the notice, that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed," as stated in the filing's standard attestation language. No sales by Slattery during the prior three months were reported.

What Was Disclosed

Replimune Group Director Joseph P. Slattery filed a Form 144 notice proposing to sell 5,200 shares of common stock with an aggregate market value of $113,360.00, originally acquired July 20, 2018, through a share exercise. No prior three-month sales were reported.